Edison Oncology Holding Corp
Edison Oncology is a clinical-stage biopharmaceutical company developing biomarker-driven, targeted therapies for cancer. They focus on identifying and developing promising drug candidates for patients with tumors most likely to respond. Combining internal development and strategic partnerships, they aim to improve cancer patient outcomes and create substantial value.
Offisielt Register
AI Kvalitetsanalyse
Tillitsscore Detaljer
Snarveier
Nettside Høydepunkter
🌟 Lignende Pålitelige Bedrifter
Kalaris Therapeutics, Inc.
Kalaris is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases. They focus on innovative retinal treatments, including TH103, a potential best-in-class anti-VEGF agent for neovascular AMD. Kalaris aims to ease patient burden and improve outcomes in retinal disease management.
ALX ONCOLOGY HOLDINGS INC
ALX Oncology is a clinical-stage biopharmaceutical company advancing therapies that boost the immune system to treat cancer. Their lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. They focus on developing novel approaches to optimize current and future standards of cancer care.
PUMA BIOTECHNOLOGY, INC.
Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer. They focus on in-licensing innovative drug candidates that have undergone clinical testing. Puma Biotechnology aims to improve cancer treatment through innovative drug development.